Impax Asset Management Group plc Has $26.90 Million Stock Holdings in Baxter International Inc. (NYSE:BAX)

Impax Asset Management Group plc reduced its stake in Baxter International Inc. (NYSE:BAX - Free Report) by 8.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 708,525 shares of the medical instruments supplier's stock after selling 61,752 shares during the period. Impax Asset Management Group plc owned 0.14% of Baxter International worth $26,903,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. First PREMIER Bank bought a new stake in shares of Baxter International during the 3rd quarter worth about $25,000. Innealta Capital LLC acquired a new position in shares of Baxter International in the second quarter valued at approximately $27,000. Fortitude Family Office LLC bought a new position in shares of Baxter International during the third quarter worth approximately $38,000. LRI Investments LLC acquired a new stake in Baxter International during the 1st quarter worth approximately $39,000. Finally, Versant Capital Management Inc boosted its stake in Baxter International by 974.2% in the 2nd quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier's stock valued at $45,000 after purchasing an additional 1,208 shares during the period. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BAX has been the subject of a number of recent analyst reports. Wells Fargo & Company cut their target price on Baxter International from $44.00 to $40.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Baxter International from a "hold" rating to a "buy" rating in a research report on Tuesday, October 22nd. Citigroup boosted their price objective on shares of Baxter International from $38.00 to $40.00 and gave the company a "neutral" rating in a research report on Tuesday, October 1st. Morgan Stanley downgraded Baxter International from an "equal weight" rating to an "underweight" rating and reduced their target price for the company from $39.00 to $30.00 in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. decreased their price target on Baxter International from $44.00 to $42.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, Baxter International has a consensus rating of "Hold" and a consensus target price of $41.20.

Baxter International Trading Up 0.8 %

Shares of BAX stock traded up $0.30 during mid-day trading on Tuesday, reaching $36.10. 2,613,828 shares of the stock traded hands, compared to its average volume of 4,030,511. The stock's fifty day simple moving average is $37.53 and its two-hundred day simple moving average is $36.16. Baxter International Inc. has a 1-year low of $32.48 and a 1-year high of $44.01. The company has a quick ratio of 0.91, a current ratio of 1.40 and a debt-to-equity ratio of 1.35. The company has a market cap of $18.42 billion, a price-to-earnings ratio of 7.43, a price-to-earnings-growth ratio of 1.21 and a beta of 0.60.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. The firm had revenue of $3.81 billion during the quarter, compared to analysts' expectations of $3.75 billion. Baxter International had a net margin of 16.51% and a return on equity of 18.06%. The company's revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.55 EPS. On average, research analysts anticipate that Baxter International Inc. will post 2.96 EPS for the current fiscal year.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.